Related Experiment Video
Updated: Jun 19, 2026
Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Current approaches to the use of sirolimus in renal transplantation
1Department of Surgery University of Texas, Division of Immunology and Organ Transplantation, 6431 Fannin, MSB 6240, Houston, TX 77030, USA.
Abstract:
Sirolimus, a macrolide with immunosuppressive properties, was introduced into clinical practice a decade ago. The optimal use of this drug remains controversial: It displays a wide range of organ and tissue toxicities owing to the critical role of its therapeutic site- the kinase mammalian target of rapamycin-in the signal transduction pathways of numerous cytokines, growth factors, hormones, and nutrients. However, it displays unique, recognized benefits for renal transplant recipients: synergistic interactions with cyclosporine and possibly tacrolimus, allowing marked reduction in exposure to the calcineurin inhibitor; reduction in the frequency of posttransplant malignancies, particularly lymphomas, Kaposi sarcomas, and hypernephromas; and modest nephrotoxicity in comparison with calcineurin inhibitors. Because of its inhibitory effects on endothelial and smooth muscle cell proliferation, sirolimus may be a useful tool to dampen chronic vasculo-obliterative processes that attenuate graft survival. With increasing experience with the drug, the true potential of sirolimus will be realized to be a critical element in the immunosuppressive matrix.
Insights
Sirolimus, an immunosuppressive macrolide, offers benefits for renal transplant recipients, including reduced calcineurin inhibitor use and lower malignancy rates. Its potential in managing graft survival is increasingly recognized.
Area of Science:
- Immunology
- Pharmacology
- Nephrology
Background:
- Sirolimus is an immunosuppressive macrolide used in clinical practice for over a decade.
- Its optimal use is debated due to potential toxicities linked to mammalian target of rapamycin (mTOR) inhibition.
- Despite toxicities, sirolimus offers unique advantages in renal transplantation.
Purpose of the Study:
- To review the benefits and challenges of sirolimus in renal transplant recipients.
- To explore its role in reducing calcineurin inhibitor exposure and posttransplant malignancies.
- To assess its impact on nephrotoxicity and graft survival.
Main Methods:
- Literature review of sirolimus use in renal transplantation.
- Analysis of clinical data regarding sirolimus efficacy and safety.
- Evaluation of sirolimus's mechanism of action in immunosuppression and anti-proliferative effects.
Main Results:
- Sirolimus demonstrates synergistic effects with cyclosporine and tacrolimus, enabling reduced calcineurin inhibitor dosage.
- It is associated with a decreased incidence of posttransplant malignancies like lymphomas and Kaposi sarcomas.
- Sirolimus exhibits comparatively modest nephrotoxicity versus calcineurin inhibitors.
- Its anti-proliferative properties may mitigate chronic vasculopathy, enhancing graft survival.
Conclusions:
- Sirolimus is a valuable component of the immunosuppressive regimen for renal transplant recipients.
- Its benefits include reduced calcineurin inhibitor toxicity, lower malignancy risk, and potential for improved graft survival.
- Further clinical experience will solidify its role in optimizing immunosuppression.
Related Concept Videos
01:28Kidney Transplant I: Introduction
01:26Kidney Transplant II: Surgical Procedure